Tuesday | Wednesday | Thursday | Friday | Saturday
6:45 am - 5:15 pm Registration - Main Lobby
7:00 am - 9:00 am Spotlight on Cost Effectiveness/Male Breast Cancer/Fertility - Stars at Night Ballroom 1&2 - 3rd Level
Chair: Dawn Hershman, MD
Columbia University Medical Center
New York, NY

Cost and Quality of Breast Cancer Care
Sharon H. Giordano, MD, MPH
UT MD Anderson Cancer Center
Houston, TX

Fertility Preservation
Kathryn J. Ruddy, MD
Mayo Clinic
Boston, MA

Male Breast Cancer
Norah Lynn Henry, MD, PhD
University of Utah
Salt Lake City, UT
7:00 am - 9:00 am Spotlight on Landscape of Mutations in Metastatic Breast Cancer - Stars at Night Ballroom 3&4 - 3rd Level
Chair: Charles M. Perou, PhD
The University of North Carolina at Chapel Hill
Chapel Hill, NC

Adrian V. Lee, PhD
University of Pittsburgh Cancer Institute
Pittsburgh, PA

ER Mutation
Svasti Haricharan
Baylor College of Medicine
Houston, TX

Mutational Processing
Reuben S. Harris, PhD
University of Minnesota
Minneapolis, MN
7:00 am - 9:00 am

POSTER SESSION 4 & continental breakfast – Hall 1




Breast Imaging - Mammography
Breast Imaging - MRI



Tumor Cell and Molecular Biology


Drug Resistance
Endocrine Therapy and Resistance
Hormonal Factors and Receptors


  Epidemiology, Risk and Prevention  
  Familial Breast Cancer - Genetic Testing
Molecular Genetics
  Prognostic and Predictive Factors  
  Predictive Biomarkers for Endocrine Therapies
Biomarkers General
  Psychosocial, QOL, and Educational Aspects  
  Disparities and Barriers to Care
Doctor-Patient Communications
Cost Effectiveness

Inflammatory Breast Cancer


9:00 am - 9:30 am



Individualizing Management of the Axillary Nodes
Tari A. King, MD
Dana-Farber Cancer Institute
Boston, MA

9:30 am - 11:30 am

Moderator: Seema Khan, SM MB
Northwestern University
Chicago, IL

9:30 am

GS5-01. Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis

  Shah C, Verma V, Sayles H, Recht A, Vicini F. Cleveland Clinic, Cleveland OH; University of Nebraska Medical Center, Omaha, NE; Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA; 21st Century Oncology/Michigan Healthcare Professionals, Farmington Hills, MI.
9:45 am

GS5-02. Axillary dissection vs. no axillary dissection in patients with cT1-T2cN0M0 breast cancer and only micrometastases in the sentinel node(s): Ten-year results of the IBCSG 23-01 trial 

  Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Egli T, Tondini C, Di Leo A, Colleoni M, Regan MM Coates AS, Gelber RD, Goldhirsch A.  International Breast Cancer Study Group Trial 23-01 investigators.
10:00 am

GS5-03. Risk of arm morbidity after local therapy in young breast cancer survivors

  Kuijer A, Dominici LS, Rosenberg SM, Hu J, Gelber S, Di Lascio S, Ruddy KJ, Wong J, Tamimi RM, Schapira L, Borges VF, Come SE, Sprunck-Harrild K, Partridge AH, King TA. Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; Diakonessenhuis Utrecht, Utrecht, Netherlands; Massachusetts General Hospital, Boston, MA; Stanford Cancer Institute and/or Stanford University, Stanford, CA; University of Colorado Cancer Center, Aurora, CO; Beth Israel Deaconess, Boston, MA; Mayo Clinic, Rochester, MN.
10:15 am

GS5-04. Prediction of occult invasive disease in ductal carcinoma in situ using deep learning features

  Lo JY, Shi B, Grimm LJ, Mazurowski MA, Baker JA, Marks JR, King LM, Maley CC, Hwang E-SS. Carl E. Ravin Advanced Imaging Laboratories, Duke University School of Medicine, Durham, NC; Duke University School of Medicine, Durham, NC; Biodesign Center for Personalized Diagnostics and School of Life Sciences, Arizona State University, Tempe, AZ.
10:30 am

GS5-05. Primary endocrine therapy for ER-positive ductal carcinoma in situ (DCIS) CALGB 40903 (Alliance)

  Hwang ES, Duong S, Bedrosian I, Allred J, Wisner D, Hyslop T, Caudle A, Guenther J, Hudis C, Winer E, Esserman L, Hylton N. Duke University, Durham, NC; Mayo Clinic, Rochester, MN; MD Anderson, Houston, TX; UCSF, San Francisco, CA; St. Elizabeth Medical Center South, Edgewood, KY; ASCO, Alexandria, VA; Dana Farber Cancer Institute, Boston, MA.
10:45 am

GS5-06. A U.S. Food and Drug Administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy

  Singh H, Howie LJ, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, Sridhara R, Ibrahim A, Goldberg K, McKee A, Beaver JA, Pazdur R. US Food and Drug Administration, Silver Spring, MD.
11:00 am

GS5-07. Weight change in postmenopausal women and breast cancer risk in the Women's Health Initiative Observational study

  Chlebowski RT, Luo J, Anderson GL, Simon M, Barrington W, Reding K, Manson JE, Rohan T, Wactawki-Wende J, Lane D, Strickler H, Mossavar-Rahmani Y, Freudenheim J, Saquib ATN, Stefanick M. City of Hope National Medical Center, Duarte, CA; Indiana University, Bloomington, IN; Fred Hutchinson Cancer Research Center, Seattle, WA; Karmanos Cancer Institute, Detroit, MI; University of Washington, Seattle, WA; Brigham And Women's Hospital, Harvard Medical School, Boston, MA; Albert Einstein College of Medicine, New York, NY; University at Buffalo, SUNY, Buffalo, NY; Stony Brook University School of Medicine, Stony Brook, NY; Sulaiman Al Rajhi College, School of Medicine, Al Bukayriyah, Saudi Arabia; Stanford University School of Medicine, Stanford, CA.
11:15 am

GS5-08. A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)

  Wärnberg F, Garmo H, Folkvaljon Y, Holmberg L, Karlsson P, Sandelin K,Linke S, Lyle S, Simin K, Leesman G, Barry T, Savala J, Whitworth P, Bremer T.
11:00 am - 5:00 pm EXHIBITS - Hall 2
11:30 am - 12:00 pm

AACR Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen® - Hall 3

  Tackling Breast Cancer Diversity
Nicholas C. Turner, PhD, FRCP
Institute of Cancer Research and Royal Marsden
12:00 pm - 1:00 pm BREAK
1:00 pm - 2:00 pm

CASE DISCUSSION 2 - Stars at Night Ballroom 1&2 - 3rd Level

  Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX

Richard L. Crownover, MD, PhD
UT San Antonio
San Antonio, TX

Matthew P. Goetz, MD
Mayo Clinic
Rochester, MN

Diane Heditsian
UCSF Breast Cancer Program
San Francisco, CA

Sibylle Loibl, MD, PhD
German Breast Group
Neu-Isenburg, GERMANY

Andrea L. Richardson, MD, PhD
Johns Hopkins Medicine
Washington, DC

Alastair Thompson, MD
UTMD Anderson Cancer Center
Houston, TX
1:00 pm - 2:00 pm BASIC SCIENCE FORUM 3 - Stars at Night Ballroom 3&4 - 3rd Level

Intratumoral Heterogeneity: Clinical Implications from Basic Science
Moderator: Elaine Mardis, PhD
Nationwide Children's Hospital
Columbus, OH

Manifestations and implications of subclonal alterations in metastatic breast cancer
Sarat Chandarlapaty, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Breast cancer intra-tumor heterogeneity and its clinical implications
Charles M. Perou, PhD
The University of North Carolina at Chapel Hill
Chapel Hill, NC

1:00 pm - 2:00 pm  DEBATE - Hemisfair Ballroom 2&3 - 3rd Level
  This house believes that all women diagnosed with metastatic breast cancer should undergo next generation sequencing? 
Chairman: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Funda Meric-Bernstam, MD
UT MD Anderson Cancer Center
Houston, TX

Fabrice André, MD, PhD
Institut Gustave Roussy
Villejuif, FRANCE

2:15 pm - 3:15 pm



Lobular Breast Cancer - Is it a Different Disease?
Moderator: Otto Metzger, MD
Dana-Farber Cancer Institute
Boston, MA

Pathology and genomics of lobular breast carcinomas and their precursors
Jorge S. Reis-FIlho, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Understanding the unique biology of ILC
Steffi Oesterreich, PhD
University of Pittsburgh
Pittsburgh, PA

Tailoring systemic therapy for patients with lobular breast cancer
Marco A. Colleoni, MD
European Institute of Oncology
Milano, ITALY

3:15 pm - 5:00 pm

Moderator: Minetta C. Liu, MD
Mayo Clinic
Rochester, MN

3:15 pm

GS6-01. Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy

Sestak I, Regan M, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J, Dowsett M. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, QMUL, United Kingdom; Dana Farber Cancer Institute, United States; Ralph Lauren Centre for Breast Cancer Research, United Kingdom; European Institute of Oncology, Italy; Kantonsspital St. Gallen, Switzerland.
3:30 pm

GS6-02. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

 Goetz MP, O'Shaughnessy J, Sledge Jr. GW, Martin M, Lin Y, Forrester T, Mockbee C, Smith IC, Di Leo A, Johnston S.  Mayo Clinic, Rochester, MN; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; Stanford University, Stanford, CA; Instituto De Investigacion Sanitaria Gregorio Marañon, Ciberonc, Geicam; Universidad Complutense, Madrid, Spain; Eli Lilly and Company, Indianapolis, IN; Hospital of Prato, Istituto Toscano Tumori, Prato, Italy; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
3:45 pm

GS6-03. Circulating tumor cells (CTCs) five years after diagnosis are prognostic for late recurrence in operable stage II-III breast cancer

  Sparano JA, O'Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang C, Sledge Jr. GW, Miller KD. Montefiore Medical Center, Albert Einstein College of Medicine; Dana Farber Cancer Institute; Fox Chase Cancer Center; Johns Hopkins Oncology Center; Mayo Clinic; Memorial Sloan Kettering Cancer Center; Stanford Cancer Center; Indiana University Cancer Center.
4:00 pm

GS6-04. The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrine therapy in HR+/HER2- breast cancer patients from ABCSG 34

  Dubsky PC, Fesl C, Singer CF, Pfeiler G, Kronenwett R, Hubalek M, Bartsch R, Stoeger H, Pichler A, Petru E, Bjelic-Radisic V, Greil R, Rudas M, Tea M-KM, Wette V, Petzner AL, Sevelda P, Egle D, Fitzal F, Exner R, Jakesz R, Balic M, Tinchon C, Bago-Horvath Z, Lax S, Regitnig P, Gnant M, Filipits M. Medical University of Vienna, Vienna, Austria; Breastcenter, Klinik St. Anna Lucerne, Lucerne, Switzerland; Myriad; Medical University of Innsbruck, Innsbruck, Austria; Medical University of Graz, Graz, Austria; LKH Hochsteiermark-Leoben, Leoben, Austria; Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University, Salzburg, Austria; Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria; Breastcenter Carinthia, St. Veit, St. Veit, Austria; Internal Medicine I, Medical Oncology, Hematology and Gastroenterology, Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria; Karl Landsteiner Institute for Gynecologic Oncology and Senology, Vienna, Austria; Institute for Pathology, LKH Graz South-West, Graz, Austria; Institute for Pathology, Medical University of Graz, Graz, Austria.
4:15 pm

GS6-05. Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer

  Formisano L, Lu Y, Jansen VM, Bauer JA, Hanker A, Gonzalez Ericsson P, Lee K-M, Nixon MJ, Guerrero-Zotano AL, Schwarz LJ, Sanders M, Sudhan D, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Mayer IA, Arteaga CL. Vanderbilt Medical Center; Robert H Lurie Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Baylor University Medical Center.
4:30 pm

GS6-06. Identifying metastatic drivers in patient-derived xenograft models of triple negative breast cancer

  Powell E, Shao J, Picon HM, Ge Z, Echeverria GV, Peoples M, Bristow C, Cai S, Tu Y, McCoy AM, Piwnica-Worms D, Draetta G, Edwards JR, Moulder Sl, Symmans WF, Heffernan TP, Liang H, Piwnica-Worms H. MD Anderson Cancer Center; Washington University in St. Louis.
4:45 pm

GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation

  Litton J, Rugo HS, Ettl J, Hurvitz S, Gonçalves A, Lee K-H, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im Y-H, Quek RGW, Tudor IC, Hannah AL, Eiermann W, Blum JL.  MD Anderson Cancer Center, Houston, TX; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; TU Muenchen III, Munich, Germany; University of California, Los Angeles, Los Angeles, CA; Institut Paoli-Calmettes, Marseille, France; Seoul National University Hospital, Seoul, Republic of Korea; Kaiser Permanente, Northern California, Velljo, CA; Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel; Banner Health, Phoenix, AZ; Hospital General Universitario Gregorio Maranon, Madrid, Spain; Institut Universitaire du Cancer Toulouse, Toulouse, France; Samsung Medical Center, Seoul, Republic of Korea; Pfizer, Inc., San Francisco, CA; Interdisziplinäres Onkologisches Zentrum Muenchen, Muenchen, Germany; Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX.
5:00 pm - 7:00 pm

POSTER SESSION 5 & reception - Hall 1




Molecular, Functional and Novel Imaging
Breast Imaging - Other Methods



Tumor Cell and Molecular Biology


Microenvironments - Stromal Epithelial Interaction
Epithelial-Mesenchymal Transition
Animal Models
Ex Vivo Models
Systems Biology of Breast Cancer
Apoptosis and Senescence


  Prognostic and Predictive Factors  
  Preclinical Studies  P5-11

Epidemiology, Risk and Prevention


Prevention - Nutritional Studies
Prevention - Behavioral Interventions
Prevention - Preclinical Studies and Model Systems
Prevention - Clinical Trials


  Psychosocial, QOL and Educational Aspects  

Psychosocial Aspects



HER2-Targeted Therapy
Advanced Therapy - Targeted
Male Breast Cancer



Ongoing Clinical Trials 3


Ongoing Trials - Prevention
Ongoing Trials - Detection
Ongoing Trials - Screening
Ongoing Trials - Targeted - PARP
Ongoing Trials - Targeted - CDH 4/6
Ongoing Trials - Targeted - Other
Ongoing Trials - DCIS
Ongoing Trials - Trial Techniques


5:00 pm - 7:00 pm SPECIAL SESSION
Stars at Night Ballroom 3&4 - 3rd Level
View from the Trenches: What Will You Do On Monday Morning?
Moderator: Lisa A. Carey, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC

Panel Members:
Matthew J. Ellis, MD, PhD
Baylor College of Medicine
Houston, TX

Susan G. Hilsenbeck, PhD
Baylor College of Medicine
Houston, TX

Patricia Spears, BS
University of North Carolina
Chapel Hill, NC

Steven E. Vogl, MD
Montefiore Medical Center
Bronx, NY

Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
Tuesday | Wednesday | Thursday | Friday | Saturday